Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages

  Albertini, Jean Paul ^a,b   McMorn, Stephen O ^c   Chen, Hongzi ^c   Mather, Richard A ^d   Valensi, Paul ^b,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL JEAN VERDIER   (France)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITÉ PARIS 13   (France)

Author keywords

E selectin; Free fatty acids; Randomized controlled trial; Rosiglitazone; Type 2 diabetes mellitus; Vascular cell adhesion molecule 1; Vascular endothelium

Indexed keywords

BIOLOGICAL MARKER; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; FEMALE; FRUCTOSAMINE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES;

EID: 34347407551     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.01.003     Document Type: Article

References (49)

1. American Heart Association. Heart disease and stroke statistics-2005 update (2005), American Heart Association, Dallas
2. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
3. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 (1997) 1230-1239
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Tailor A., and Granger D.N. Role of adhesion molecules in vascular regulation and damage. Curr Hypertens Rep 2 (2000) 78-83
6. Albertini J.P., Valensi P., Lormeau B., et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care 21 (1998) 1008-1013
7. Meigs J.B., Hu F.B., Rifai N., and Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 (2004) 1978-1986
8. Erbe D.V., Wolitzky B.A., Presta L.G., et al. Identification of an E-selectin region critical for carbohydrate recognition and cell adhesion. J Cell Biol 119 (1992) 215-227
9. Stad R.K., and Buurman W.A. Current views on structure and function of endothelial adhesion molecules. Cell Adhes Commun 2 (1994) 261-268
10. Taniguchi A., Fukushima M., Nakai Y., et al. Soluble E-selectin, leptin, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Metabolism 54 (2005) 376-380
11. Leinonen E., Hurt-Camejo E., Wiklund O., et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166 (2003) 387-394
12. Natali A., Toschi E., Baldeweg S., et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 55 (2006) 1133-1140
13. Kessler L., Wiesel M.L., Attali P., et al. von Willebrand Factor in diabetic angiopathy. Diabetes Metab 24 (1998) 327-336
14. Vinik A.I., Erbas T., Park T.S., Nolan R., and Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476-1485
15. Lormeau B., Aurousseau M.H., Valensi P., Paries J., and Attali J.R. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients. Metabolism 46 (1997) 1074-1079
16. Nordt T.K., Peter K., Ruef J., Kubler W., and Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemostasis 82 Suppl. 1 (1999) 14-18
17. Boneu B., Abbal M., Plante J., and Bierme R. Letter: factor-VIII complex and endothelial damage. Lancet 1 (1975) 1430
18. Ye J.M., Dzamko N., Cleasby M.E., et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47 7 (2004) 1306-1313
19. Miyazaki Y., Glass L., Triplitt C., et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44 (2001) 2210-2219
20. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 (1999) 253-259
21. Wang N., Verna L., Chen N.G., et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 277 (2002) 34176-34181
22. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 15 (1998) 539-553
23. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
24. Jager A., van Hinsbergh V.W., Kostense P.J., et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 49 (2000) 485-491
25. Sasaki M., Jordan P., Welbourne T., et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol 5 (2005) 3
26. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1763
27. Yudkin J.S., Panahloo A., Stehouwer C., et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43 (2000) 1099-1106
28. Sidhu J.S., Cowan D., and Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94 (2004) 151-156
29. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
30. Chiu J.J., Lee P.L., Chen C.N., et al. Shear stress increases ICAM-1 and decreases VCAM-1 and E-selectin expressions induced by tumor necrosis factor-[alpha] in endothelial cells. Arterioscler Thromb Vasc Biol 24 (2004) 73-79
31. Bennett S.M., Agrawal A., Elasha H., et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Med 21 (2004) 415-422
32. Thögersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
33. Blann A.D. von Willebrand Factor and atherosclerosis. J Intern Med 237 (1995) 432-434
34. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 15 (2001) 44-54
35. Freed M.I., Fuell D., Menci L., Heise M., and Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia 43 (2000) A267
36. Mohanty P., Aljada A., Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
37. Wang T.D., Chen W.J., Cheng W.C., et al. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in non-diabetic patients with the metabolic syndrome. Am J Cardiol 98 (2006) 1057-1062
38. Garg R., Kumbkarni Y., Aljada A., et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36 (2000) 430-435
39. Chu J.W., Abbasi F., Lamendola C., et al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res 2 (2005) 37-41
40. Ghanim H., Garg R., Aljada A., et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86 (2001) 1306-1312
41. Natali A., Baldeweg S., Toschi E., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
42. Wang T.D., Chen W.J., Lin J.W., Chen M.F., and Lee Y.T. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in non-diabetic patients with the metabolic syndrome. Am J Cardiol 93 (2004) 362-365
43. Laakso M., Edelman S.V., Brechtel G., and Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85 (1990) 1844-1852
44. Mather K., Laakso M., Edelman S., Hook G., and Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 279 (2000) E1264-E1270
45. Kuboki K., Jiang Z.Y., Takahara N., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101 (2000) 676-681
46. Tripathy D., Mohanty P., Dhindsa S., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52 (2003) 2882-2887
47. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 6 (2006) 177-181
48. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48 (2005) 1726-1735
49. Sobel B.E., Frye R., and Detre K.M. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 107 (2003) 636-642